Athyrium provides USD 30 million in convertible note financing to Hansa Biopharma

Hansa Biopharma AB (publ), listed on Nasdaq Stockholm, has announced that it has entered into a convertible note purchase agreement with certain funds managed by Athyrium Capital Management (Athyrium), comprising USD 30 million aggregate principal amount of unsecured convertible senior notes. The convertible note financing extends the company’s runway into mid-2027 and ensures a robust launch of imlifidase in the US, subject to approval.

Mannheimer Swartling advised Athyrium on Swedish legal matters in the transaction. The team consisted of Jakob Wijkander, Johan Berg, Elias Lindberg Wahlström, Linn Gårdevall, Albin Arousell, Andreas Zettergren, Wilhelm Westberg, Niklas Hagbard and Simon Österlin.